Interactive Decision Support Tool


Program Content


  • Monitoring Response to BCR-ABL1 inhibitors in CML
    Chronic Myeloid Leukemia Interactive Decision Support Tool: Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 30, 2022

    Expires: March 29, 2023


cover img faculity

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

cover img faculity

Daniel J. DeAngelo, MD, PhD

Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director, Adult Leukemia Program
Department of Medical Oncology
Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Boston, Massachusetts


cover img faculity

Smith B Douglas

cover img faculity

Michael J. Mauro, MD

Associate Professor
Knight Cancer Institute, Center for Hematologic Malignancies
Oregon Health and Science University
Portland, Oregon

cover img faculity

Neil P. Shah, MD, PhD

Assistant Professor
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

ProCE Banner


Novartis Pharmaceuticals Corporation

Pfizer, Inc.